Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

AbbVie acquires options to Turnstone immunotherapies

Alicia Parker
October 13, 2017 7:52 PM UTC

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad-MG1-MAGEA3.

By combining oncolytic viruses with cancer vaccines, Turnstone aims to develop products with efficacy advantages over each individual modality (see BioCentury, Feb. 22, 2016)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.

Turnstone Biologics Inc.